CO-SPATIAL-CORP
23.5.2024 18:01:32 CEST | Business Wire | Press release
Spatial Corp, the leading software development toolkit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, announced today that it has added HOOPS Communicator, developed by Tech Soft 3D, to complement and extend its portfolio of component technologies. With the addition of HOOPS Communicator to Spatial’s 3D components portfolio, Spatial now enables web-based visualization of and interaction with 3D data for a diverse range of design, engineering and manufacturing workflows.
Adding HOOPS Communicator to Spatial’s product portfolio allows its customers to expand their applications to the web while reusing their IP from traditional desktop applications. As a result, Spatial’s customers can leverage many new opportunities on the web, including extended customer-reach, more access control, and less costly distributions, updates and maintenance.
“We are excited to enhance our portfolio by adding HOOPS Communicator. This addition enables Spatial customers to seamlessly implement powerful web applications for various engineering workflows, building on robust 3D modeling kernel and 3D InterOp components for data conversion, preparation and reuse,” said Jean-Marc Guillard, CEO, Spatial Corp.
One of Spatial’s newest customers is a vivid example of the tight integration of HOOPS Communicator with the 3D modelers CGM and ACIS as well as 3D InterOp. The customer plans to release a new web-based application for architectural, engineering and construction (AEC) workflows, which allows users to digitally create, review and finalize designs for homes, buildings and plants – all before costly construction begins – in collaboration with stakeholders across globally distributed sites.
Additional examples of web-based workflows enabled by HOOPS Communicator used in conjunction with Spatial’s 3D modelers CGM and ACIS and 3D InterOp include:
- Virtual twin applications for numerous manufacturing processes such as sheet metal fabrication, 3D printing and multi-axis milling, as well as a wide range of robotic systems
- Collaborative inspection applications for parts and assemblies with both geometry and product manufacturing information (PMI)
- On-demand catalogs for 3D parts and assemblies for diverse kinds of industrial applications
Like HOOPS Visualize for developing native applications, which Spatial has integrated with its SDKs and resold since 2012, HOOPS Communicator provides comprehensive out-of-the-box API functionality for a variety of engineering workflows on the web. Such functionality avoids having to recreate the same functionality in WebGL or with open-source frameworks. Furthermore, unlike OEM solutions, HOOPS Communicator allows custom interaction with 3D data.
Contact Spatial today to learn more about how HOOPS Communicator can unlock the power of the web for 3D workflows.
About Spatial
Spatial Corp, a Dassault Systèmes subsidiary, is a provider of 3D software development toolkits for technical applications across a broad range of industries. Spatial 3D modeling, 3D visualization, and CAD translation software development toolkits help application developers deliver market-leading products, maintain focus on core competencies, and reduce time-to-market. For over 35 years, Spatial’s 3D software development toolkits have been adopted by many of the world’s most recognized software developers, manufacturers, research institutes, and universities. Headquartered in Broomfield, Colorado, Spatial has offices in the USA, France, Germany, Japan, China, and the United Kingdom. For more information, visit www.spatial.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528574696/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom